Human T-lymphotropic virus type 1 (HTLV-1) causes the debilitating neuroinflammatory disease HTLV-1-associated myelopathy-tropical spastic paraparesis (HAM-TSP) as well as adult T-cell leukemia-lymphoma (ATLL). In patients with HAM-TSP, HTLV-1 infects mainly CCR4+ T cells and induces functional changes, ultimately causing chronic spinal cord inflammation. We evaluated mogamulizumab, a humanized anti-CCR4 monoclonal antibody that targets infected cells, in patients with HAM-TSP.
T h e ne w e ngl a nd jou r na l o f m e dicine H uman T-lymphotropic virus type 1 (HTLV-1) infects millions of persons worldwide 1 and is the cause of adult T-cell leukemia-lymphoma (ATLL) 2, 3 and HTLV-1-associated myelopathy-tropical spastic paraparesis (HAM-TSP). 4, 5 The extent of infection, as indicated by the proviral load, is well correlated both with the risk of ATLL 6 and with HAM-TSP prognosis. [7] [8] [9] Patients with HAM-TSP may have chronic spinal cord inflammation and progressive myelopathic symptoms that are similar to those of multiple sclerosis. 10 Currently available treatments -namely, glucocorticoids and interferon-α -focus on suppressing inflammation rather than on attacking infected cells and reducing the proviral load. 11, 12 Studies have shown that HTLV-1 infects mainly CCR4+ T cells and converts them into abnormal cells that drive chronic inflammation in patients with HAM-TSP. 13 ,14 ATLL cells also frequently express CCR4. 15 A humanized anti-CCR4 monoclonal antibody called mogamulizumab has been approved in Japan for the treatment of ATLL 16 and is known to eliminate CCR4-expressing cells by means of antibody-dependent cellular cytotoxic effects. 17 When tested on cells obtained from patients with HAM-TSP, mogamulizumab effectively reduced both the proviral load and inflammatory activity in cell cultures. 18 In this investigator-led, phase 1-2a study, we examined the safety profile and effectiveness of mogamulizumab in patients with HAM-TSP. Although high doses of the drug (1.0 mg per kilogram of body weight per week) have been appropriate to combat an aggressive cancer such as ATLL, minimizing adverse effects is a high priority in the treatment of a chronic disease. We therefore conducted an uncontrolled, open-label, dose-escalation study to measure the pharmacokinetics and dose-limiting toxic effects, starting from a dose as low as 0.003 mg per kilogram, which was administered during the phase 2 study as a single dose every 8 weeks. In addition, we addressed concerns that mogamulizumab may eliminate regulatory T (Treg) cells, eliciting autoimmunity that could exacerbate HAM-TSP. 19 Laboratory and clinical tests were used to explore the effectiveness of mogamulizumab at reducing the proviral load, inflammation, and clinical symptoms of HAM-TSP.
Me thods

Study Design and Oversight
The study was designed as an open-label, phase 1-2a trial to assess the safety, pharmacokinetics, and efficacy of mogamulizumab in patients with glucocorticoid-refractory HAM-TSP. The study was performed at St. Marianna University Hospital in Kawasaki, Japan. In addition to the authors, an independent group of investigators at the Kitasato Academic Research Organization performed the data analysis. The protocol, available with the full text of this article at NEJM.org, was approved by the institutional review board. All the patients provided written informed consent before enrollment. Mogamulizumab (KW-0761) was donated (with safety information included) by Kyowa Hakko Kirin, which had no role in any other aspect of the study. The study was designed by the authors, who also collected the data, analyzed it in collaboration with Kitasato investigators, vouch for the accuracy and completeness of the data and analyses, and confirm adherence of the study to the protocol. No one who is not an author contributed to the manuscript.
Inclusion and Exclusion Criteria
Patients who were enrolled in the trial had received a diagnosis of HAM-TSP on the basis of World Health Organization guidelines. 20 Despite taking oral prednisolone continuously at a fixed dose of less than 10 mg per day for 3 months or more, the patients had a Osame Motor Disability Score (assessed on a scale from 0 to 13, with higher scores indicating greater disability) 21 that remained unchanged, and the concentration of neopterin, a marker of immune-system activation, in their cerebrospinal fluid (CSF) remained at or above 5 pmol per milliliter. (Details regarding the Osame Motor Disability Scoring system are provided in Table S1 in the Supplementary Appendix, available at NEJM.org.) These criteria were chosen in order to select a pool of participants who did not have a satisfactory response to glucocorticoid treatment and who therefore were good candidates for an additional treatment.
To participate in the motor-ability assessments, participants had to be able to walk 10 m, although canes or walkers could be used for support. Persons with a severe infection or autoimmune disorder were excluded. Details are provided in the protocol and the Supplementary Appendix.
Treatment
Phase 1 was a dose-escalation study in which participants received an intravenous infusion of mogamulizumab once (on day 1) and were observed until day 85. The study followed a 3+3 design with five dose levels (0.003 mg per kilogram, 0.01 mg per kilogram, 0.03 mg per kilogram, 0.1 mg per kilogram, and 0.3 mg per kilogram). Patients were enrolled sequentially, starting from the lowest dose, and higher dose levels were opened when at least three patients had had no dose-limiting toxic event for at least 1 week after the infusion. If a dose-limiting event occurred, three more patients were added to the group. If three patients had a dose-limiting toxic event, the dose would be deemed to be the maximum tolerated dose. Disease severity was not a factor in the assignment of patients to dose groups, so groups did not include patients with equal disease severity. Details are provided in the Supplementary Methods section in the Supplementary Appendix.
The phase 2a study was designed to involve the same cohort of patients from the phase 1 portion of the study and to test repeated mogamulizumab infusions over a period of 24 weeks. Screening for the phase 2a study was conducted at the end of phase 1 (day 85). Patients in the phase 2a study initially continued to receive the same dose that they had received in phase 1. Infusions of 0.003 mg per kilogram, 0.01 mg per kilogram, or 0.03 mg per kilogram were administered at 8-week intervals, and infusions of 0.1 mg per kilogram or 0.3 mg per kilogram at 12-week intervals. If patients did not meet the criteria for participation in the phase 2 study (e.g., they had neutralizing antibody-positive status or a neutrophil level of ≤1500 per cubic millimeter), treatment was postponed until the criteria were met. In cases in which the proviral loads after the infusion did not decrease to 40% or lower, the patient was moved up to the next dose level if the side-effect profile was not limiting.
Oral prednisolone that had been prescribed before the trial began was continued without changes to the dose during the clinical trial period. The use of other immunomodulating drugs that are sometimes prescribed for HAM-TSP (e.g., glucocorticoid pulse therapy and interferon-α) was prohibited. Although physical therapy regimens that were in place before the trial were continued, no changes to the regimens were allowed. Limited changes to doses of spasmolytic, urinary, and analgesic medications were allowed (see the protocol).
Disease Evaluation
The primary end points were safety and pharmacokinetics. Safety concerns included dose-limiting toxic events and the maximum tolerated dose, adverse events, and the expression of antimogamulizumab neutralizing antibodies. Adverse events were evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Pharmacokinetic analysis consisted of the documentation of chronologic changes in plasma and CSF concentrations of mogamulizumab after a single infusion of mogamulizumab. The secondary end point was drug efficacy as determined by the measurement of changes in the proviral load in peripheralblood mononuclear cells (PBMCs).
Several other exploratory assessments were also conducted. Clinical evaluations included assessment of mobility, dysuria, and sensory dysfunction and the patient's global assessment of the effect of symptoms related to HAM-TSP on activities of daily life. Mobility was measured with the use of the Modified Ashworth Scale (assessing knee extensor and flexor muscles, with grades of 0, 1, 1+, 2, 3, and 4 and with higher grades indicating more severe spasticity; definitions of the grades are provided in Table S3 in the Supplementary Appendix), 22 the Osame Motor Disability Score, the 10-m timed walk (i.e., the time required to walk 10 m), the timed up-andgo test (i.e., the time required to rise from a chair, walk 3 m away, turn, walk back, and sit down again), 23 and the distances that could be walked in 2 minutes and in 6 minutes. Dysuria was measured by means of the International Prostate Symptom Score (range, 0 to 35, with higher scores indicating more difficulty urinating), 24 the Overactive Bladder Symptom Score (range, 0 to 15, with higher scores indicating T h e ne w e ngl a nd jou r na l o f m e dicine more severe urinary urgency), 25 the International Consultation on Incontinence QuestionnaireShort Form (range, 0 to 21, with higher scores indicating more severe incontinence), 26 and the Nocturia-Quality of Life questionnaire (range, 0 to 100, with lower scores indicating lower quality of life). 27 Sensory dysfunction (lowerlimb numbness or pain) and the patient's global assessment were measured with the use of a 100-mm visual-analogue scale (with higher values indicating a more severe condition).
Laboratory analyses included complete blood counts, blood chemical testing, CSF analysis, plasma and CSF concentrations of mogamulizumab, proviral loads in PBMCs and CSF cells, CXCL10 concentration in CSF, neopterin concentration in CSF, testing for anti-mogamulizumab neutralizing antibodies, cellular analyses (including the ratio of CCR4+ PBMCs and the analysis of cell adhesion molecule 1 [CADM1] and CD7 expression in CD4 T cells), and integration-site analyses to determine the clonality of infected cells. Major clones were identified and interpreted to be cell populations that were at high risk for progression to ATLL. 28 CADM1 is a specific marker molecule of HTLV-1-infected cells, and CADM1+CD7− CD4 T cells show high clonality and have several characteristics of ATLL cells, as has been reported previously. 29, 30 Further details are provided in the Supplementary Methods section in the Supplementary Appendix.
Statistical Analysis
Data from all the patients in the study were used to assess the efficacy, safety, and pharmacokinetics of the treatment. The last-observationcarried-forward method was used to impute missing data on efficacy for patients who discontinued treatment. Descriptive statistics were used to summarize patients' characteristics and the findings. Spearman's rank-correlation coefficients were calculated to investigate dose-dependent changes in CCR4+ cells, the proviral load in PBMCs, and the CSF concentrations of CXCL10 and neopterin during the phase 1 study and to analyze relationships between changes in the proviral load in PBMCs and the CSF biomarkers (CXCL10 and neopterin). We computed 95% confidence intervals (two-sided) for the mean changes in the laboratory and clinical findings and for Spearman's rank-correlation coefficients.
R esult s
Patients
From November 2013 through January 2015, a total of 21 patients were enrolled in phase 1 of the study. Details regarding the characteristics of the patients are provided in Table S4 in the Supplementary Appendix. Patients were administered mogamulizumab at the following sequential doses: 0.003 mg per kilogram (3 patients), 0.001 mg per kilogram (3 patients), 0.03 mg per kilogram (6 patients; a dose-limiting toxic event occurred in 1 patient, and 3 patients were added to the group), 0.1 mg per kilogram (3 patients), and 0.3 mg per kilogram (6 patients). Because no dose-limiting toxic events occurred at the dose of 0.3 mg per kilogram, it was set as the maximum dose, and 3 additional patients were enrolled at this dose, per the study protocol. Of these 21 patients, 19 continued on to the phase 2a study, in which all 19 completed the 24-week course of repeated mogamulizumab infusions. (Details regarding the doses are provided in Table S2 in the Supplementary Appendix.) During the course of the study, the treatment regimen of only 1 patient was modified: Patient 12 began receiving propiverine (an anticholinergic drug to control bladder spasms) on day 57 of the phase 1 study.
Safety
Adverse events that were severe or that occurred in at least 3 of 21 patients are listed in Table 1 . Other adverse events that were considered by the investigators to be related to the study drug are listed in Table S5 in the Supplementary Appendix. The most frequent reactions were rash (in 48% of patients) and lymphopenia and leukopenia (each in 33%), and almost all the adverse events were of grade 1 or 2. One patient had a grade 3 dose-limiting toxic event (elevation in the aspartate aminotransferase level), which resolved within 2 weeks. No adverse events at or above grade 4 were noted. No deaths occurred during the course of the study. A single case each of an infusionrelated reaction (grade 1), a herpes zoster infection (grade 2), and a herpes labialis infection (grade 1) occurred. Adverse events occurred more frequently after the receipt of higher doses of mogamulizumab (Table S6 in the Supplementary Appendix). Anti-mogamulizumab neutraliz-ing antibodies were detected in 3 of 21 patients (14%) during the phase 2a study (Table S2 in the Supplementary Appendix).
Pharmacokinetics
The peak plasma concentrations and the area under the curve after a single infusion of mogamulizumab increased according to increasing dose (from 0.003 mg per kilogram to 0.3 mg per kilogram) (Fig. S1A and Table S7 in the Supplementary Appendix). At the two lowest dose levels (0.003 mg per kilogram and 0.01 mg per kilogram), the plasma concentrations of mogamulizumab became almost undetectable by day 57. However, at doses of 0.03 mg or more per kilogram, mogamulizumab was detected even at day 85. In addition, the CSF concentrations of mogamulizumab in nearly all the patients were below the limit of detection (<5 ng per milliliter). In two of the six patients who received an infusion at the * Listed are adverse events that were reported in at least 3 of 21 patients or that were of grade 3 severity. † Listed are drug-related adverse events that were considered by the investigators to be possibly, probably, or definitely related to mogamulizumab. ‡ Cases of lymphopenia and leukopenia were considered by the investigators to be non-drug-related if either there was only one occurrence or if there was judged to be a primary cause that was unrelated to mogamulizumab (e.g., if the event occurred in conjunction with a bout of illness such as the common cold). 
Efficacy
The effectiveness of mogamulizumab was evaluated in all 21 patients who participated in the phase 1 study. In PBMCs, the frequency of CCR4+ cells and the HTLV-1 proviral load both decreased promptly after the infusion (Fig. 1A) . At day 15, the proviral load had decreased by 64.9% (95% confidence interval [CI], 51.7 to 78.1). Inflammatory markers in the CSF also decreased; at day 29, the neopterin concentration had decreased by 21.0% (95% CI, 10.7 to 31.4), and the CXCL10 concentration by 37.3% (95% CI, 24.8 to 49.8) (Fig. 1B) . These responses were dose-dependent (r = 0.50 to 0.62 by Spearman's rank correlation). At day 29, the HTLV-1 proviral copy number per milliliter of CSF had decreased by 41.4% (95% CI, 24.6 to 58.2). Details are provided in Figures S1 and S2 in the Supplementary Appendix. Clinical measures also improved during the phase 1 study. Muscle tone improved markedly. The percentage of patients with a Modified Ashworth Scale grade of 2 or higher decreased from 48% at baseline to 0% by day 7 and subsequently held steady at approximately 5 to 10% (Fig. 2A) . By day 29, the percentage of participants who needed support to walk (Osame Motor Disability Score, ≥5) had decreased from 71% to 52% (Fig. 2B) .
The 19 patients who were enrolled in the phase 2a study received multiple mogamulizumab infusions with intrapatient dose escalation allowed (Table S2 in the Supplementary Appendix). These multiple infusions were sufficient to sustain the favorable reductions in the proviral load and the levels of inflammatory markers that were seen in the phase 1 study. At week 24 of the phase 2a study, the mean percent reduction in the proviral load in PBMCs was 46.4% (95% CI, 28.7 to 64.1), and the mean percent reduction in the neopterin concentration in CSF was 45.1% (95% CI, 30.0 to 60.3) (Fig. 3A) . In addition, at week 24, the mean percent reduction in the CXCL10 concentration in CSF was 28.9% (95% CI, 14.9 to 42.9), and the mean percent reduction in the proviral copy number per milliliter of CSF was 62.5% (95% CI, 50.5 to 74.4).
Improvements in clinical measures were sustained throughout the phase 1-2a study (Fig. 3B , and Fig. S7 in the Supplementary Appendix).
Patients' global-assessment scores were markedly reduced, from a mean of 75.7 (95% CI, 67.8 to 83.6) on day 0 of the phase 1 study to 53.7 . Nearly all the CADM1+CD7+ and CADM1+CD7− CD4 T cells 29 disappeared the day after infusion at the highest dose, and this effect was sustained (Fig. 4) . Results varied considerably according to dose. On average, however, from day 0 (the day before infusion) to the week 24 visit, the absolute number of CADM1+ CD4 T cells decreased from 103. 
Discussion
The anti-CCR4 antibody mogamulizumab appeared to selectively target and reduce the number of HTLV-1-infected cells, a known indicator of HAM-TSP prognosis. [7] [8] [9] The resulting reduction in the levels of inflammatory biomarkers in CSF and the amelioration of clinical symptoms highlight the potential efficacy of this new treat- T h e ne w e ngl a nd jou r na l o f m e dicine ment for HAM-TSP. In addition, toxic events were mainly of low grade. The data reported here also support our previously published conclusions.
14 The observation that mogamulizumab, even at undetectable levels in the CSF, reduced the number of infected cells in CSF (Fig. S1D in the Supplementary Appendix) supports our hypothesis that infected cells are continuously recruited to the CSF rather than proliferating in the central nervous system. 13, 31 Also, the corresponding reduction in the levels of inflammatory markers that are correlated with disease activity (namely, CXCL10, neopterin, and the CSF cell count) 32 substantiates the longheld belief that HTLV-1-infected cells are the source of central nervous system inflammation rather than only the initial trigger for a runaway immune response. 12, 33, 34 The treatment also produced considerable, long-lasting clinical benefits, even in patients who had not had a response to glucocorticoids. Because the inclusion criteria stipulated that the Osame Motor Disability Score and the Modified Ashworth Scale score had to have been stable for at least 3 months before treatment, the improvements we documented were presumed to be drugrelated. The improvements with regard to motor ability were most pronounced in patients who had an early stage of disease (Fig. S8 in the Supplementary Appendix).
The clinical effects appeared very quickly, long before any changes in the markers of inflammation in the central nervous system. Perhaps infected cells can directly affect the central nervous system by an unknown additional pathogenic mechanism.
Our trial was too small and too short to evaluate the clinical safety of mogamulizumab.
In a previous trial that tested a higher dose of mogamulizumab (1.0 mg per kilogram per week) in patients with ATLL, transient infusion reactions and severe, long-lasting skin reactions were very common. 16 By contrast, we observed only one infusion reaction and no severe skin reactions. The lower dose with the longer interval between administrations that was used in our study is probably the relevant factor, although the glucocorticoids that were taken concurrently by our patients may also have helped to prevent such side effects. Although immune hyperactivation due to the loss of Treg cells was a concern for the investigators in the trial involving patients with ATLL, 19, 35 we found that a substantial population of FOXP3+ cells survived the treat- ments, and we observed no increase in the level of Tax-specific cytotoxic T lymphocytes ( Fig. S12B and S12C in the Supplementary Appendix). We noted several cases of lymphopenia and an increase in the incidence of herpes infection (Table 1, and Table S5 in the Supplementary Appendix), which suggests that immune deficiency may be of concern.
In conclusion, mogamulizumab decreased the number of HTLV-1-infected cells and the levels of inflammatory markers. Rash was the major side effect. Our trial was limited by a small sample size and short duration of treatment and follow-up; a long-term safety trial (UMIN trial number, UMIN000019942) is ongoing. 
